First-Time FounderAbout
Regenova Pharmaceuticals is a quantum AI-powered antibody discovery platform that accelerates drug development from 12 months to 4-8 weeks. The company uses its proprietary TRACE platform to design antibodies for oncology and infectious diseases, delivering life-saving therapies with 98% predictive accuracy, 10× faster timelines, and 65% lower costs.
Traction & Metrics
Users & Clients
3
Users
Products
VideoTRACE Platform
End-to-end Quantum computing enabled antibody design platform that streamlines drug development from target discovery to IND-ready candidates. Features include target identification, antibody sequence prediction, 3D structural modeling, drug-target binding affinity prediction, in silico toxicity profiling, and first-in-human safety dose prediction. Built on proprietary oncology and virology datasets with 98% predictive accuracy, validated through co-development with CancerFree Bio and IBM Quantum partnership.
Click to read more
Multi-Cancer Monoclonal Antibody
Lead monoclonal antibody (mAb) candidate targeting colorectal cancer, pancreatic cancer, non-small cell lung cancer, and cervical cancer. Designed in TRACE platform, validated in silico, and entering wet-lab testing. Multi-indication potential from a single antibody scaffold with high licensing potential across multiple indications.
Click to read more
Anti-HER2 Antibody
Monoclonal antibody against HER2 Breast cancer targeting novel epitope to better bind.
Biodefense- Pan Filo Virus Antibody
Antibody therapy against all viruses in Filovirus family. Addresses biosafety level 4 pathogens that traditional labs cannot safely handle, protecting 300M+ people vulnerable to pathogens Big Pharma cannot touch.
Click to read more
TRACE Platform
End-to-end Quantum AI antibody design platform that streamlines drug development from target discovery to IND-ready candidates. Features include target identification, antibody sequence prediction, 3D structural modeling, drug-target binding affinity prediction, in silico toxicity profiling, and first-in-human safety dose prediction. Built on proprietary oncology and virology datasets with 98% predictive accuracy, validated through co-development with CancerFree Bio and IBM Quantum partnership.
Click to read more
Multi-Cancer Monoclonal Antibody
Lead monoclonal antibody (mAb) candidate targeting colorectal cancer, pancreatic cancer, non-small cell lung cancer, and cervical cancer. Designed in TRACE platform, validated in silico, and entering wet-lab testing. Multi-indication potential from a single antibody scaffold with high licensing potential across multiple indications.
Click to read more
Pediatric HSV Antibody
First-mover antibody therapy for pediatric herpes simplex virus (HSV) infections, addressing a critical unmet need in rare viral diseases.
Click to read more
Nipah Virus Antibody
Antibody therapy for Nipah virus, which is 700× deadlier than COVID-19. Addresses biosafety level 4 pathogens that traditional labs cannot safely handle, protecting 300M+ people vulnerable to pathogens Big Pharma cannot touch.
Click to read more
Updates
Moving into commercialization
We received approval from AWS IW grant program and now moving our disocvery model from Quantum simulator to Quantum computing hardware from IonQ.